Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3359533 | 0.89 | TSHR (0.35) | TSHR | |
| SCHEMBL5761384 | 0.82 | TSHR (0.42) | CA14CA12TSHR | |
| SCHEMBL7735643 | 0.81 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1036103 | 0.78 | — | — | |
| SCHEMBL20661277 | 0.77 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL25365898 | 0.76 | — | — | |
| SCHEMBL1171077 | 0.76 | — | — | |
| SCHEMBL7403671 | 0.76 | — | — | |
| SCHEMBL2101489 | 0.76 | — | — | |
| SCHEMBL25807 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728883-B | Ibuprofen ester prodrug, pharmaceutical composition, preparation method and application | 南京海融医药科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-113831342-B | Ketorolac derivative, pharmaceutical composition, and preparation method and application thereof | 南京海融医药科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3587403-B1 | N-SUBSTITUTED IMIDAZOLE CARBOXYLATE COMPOUND, PREPARATION METHOD AND USE | WEST CHINA HOSPITAL SICHUAN UNIV (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230000812-A1 | IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11208385-B2 | N-substituted imidazole carboxylate compound, preparation method and use | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2021-12-28 | — | — | US | disclosed |
| CN-107652239-B | N-substituted imidazole carboxylic ester compound, preparation method and application | 四川大学华西医院 | 2020-08-04 | — | — | CN | disclosed |
| US-20200231546-A1 | N-SUBSTITUTED IMIDAZOLE CARBOXYLATE COMPOUND, PREPARATION METHOD AND USE | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2020-07-23 | — | — | US | disclosed |
| US-5587374-A | BACTERICIDES TREATING INFECTIONS | GLAXO SPA (IT) | 1996-12-24 | — | — | US | disclosed |
| EP-0495953-B1 | 10-(1-Hydroxyethyl)-11-oxo-1-azatricyclo[7.2.0.0(3,8)]undec-2-ene-2-carboxylic acid esters and a process for preparing thereof | GLAXO SPA (IT) | 1994-06-08 | — | — | EP | disclosed |
| EP-0495953-A1 | 10-(1-Hydoxyethyl)-11-oxo-1-azatricyclo(7.2.0.0(3,8)undec-2-ene-2-carboxylic acid esters and a process for preparing thereof. | GLAXO SPA (IT) | 1992-07-29 | — | — | EP | disclosed |
| WO-1992003437-A1 | 10(1-HYDROXYETHYL)-11-OXO-1-AZATRICYCLO[7.2.0.0.3.8]UNDEC-2-ENE-2-CARBOXYLIC ACID ESTERS AND A PROCESS FOR PREPARING THEREOF | GLAXO S.P.A. (IT) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000812-A1 | IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION | PTGER1, CYP4A11, FABP4 | SMN1; SMN2 967/4885CA14 3653/4885CA12 3846/4885 |
| US-20230134672-A1 | KETOROLACO DERIVATIVE, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4A11, CYP4F11 | SMN1; SMN2 3112/4885CA14 3748/4885CA12 3744/4885 |
| US-11208385-B2 | N-substituted imidazole carboxylate compound, preparation method and use | NR3C1, CYP2E1, CYP3A5 | SMN1; SMN2 1854/4885CA14 4144/4885CA12 4345/4885 |
| US-20200231546-A1 | N-SUBSTITUTED IMIDAZOLE CARBOXYLATE COMPOUND, PREPARATION METHOD AND USE | CHRM1, CYP2C18, CYP2E1 | SMN1; SMN2 735/4885CA14 4181/4885CA12 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.